Generics - Actavis, Regulation

Filter

Current filters:

ActavisRegulation

Popular Filters

1 to 25 of 26 results

Actavis files ANDA for generic of Purdue's Butrans

Actavis files ANDA for generic of Purdue's Butrans

26-09-2014

Ireland-headquartered generics major Actavis has filed an Abbreviated New Drug Application with the US…

ActavisAnalgesiaBuprenorphineButransGenericsLegalPurdue PharmaRegulationUSA

Actavis confirms patent challenge for generic Neupro

Actavis confirms patent challenge for generic Neupro

23-08-2014

Ireland-headquartered generics major Actavis on Friday confirmed that it has filed an Abbreviated New…

ActavisGenericsLegalNeuproNeurologicalPatentsRegulationUCBUSA

Actavis confirms patent challenge to Duchesnay’s Diclegis

Actavis confirms patent challenge to Duchesnay’s Diclegis

12-07-2014

Ireland-based generics major Actavis on Friday confirmed that it has filed an Abbreviated New Drug Application…

ActavisDiclegisDuchesnayGenericsPatentsRegulationUSAWomen's Health

Actavis and Forest to divest four generics to gain FTC OK for merger

01-07-2014

In order for Ireland-headquartered generics major Actavis to complete its previously-announced $25 billion…

ActavisForest LaboratoriesGeneric pharmaceuticalsGenericsHealth Medical PharmaMedicinePharmaceutical industryPharmacologyRegulationUSA

Actavis files for generic version of Acorda’s Ampyra

Actavis files for generic version of Acorda’s Ampyra

27-06-2014

US biotech firm Acorda Therapeutics has been advised that Ireland-headquartered generics major Actavis…

Acorda TherapeuticsActavisAmpyraGenericsHealth Medical PharmaMedicinePharmaceutical sciencesPharmacologyRegulationUS Food and Drug AdministrationUSA

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

14-05-2014

US generic drugmaker Mylan says it has launched Olanzapine Orally Disintegrating tablets (ODT), 5mg,…

ActavisEli LillyExalgoGenericsMallinckrodtMarkets & MarketingMylanNeurologicalRegulationUSAZyprexa

Vivus says Actavis has filed ANDA for generic Qsymia

Vivus says Actavis has filed ANDA for generic Qsymia

10-05-2014

US drug developer Vivus disclosed on Friday that the company had received notice from generics major…

ActavisGenericsMetabolicsPatentsQsymiaRegulationUSAVivus

US FDA approves NDA from Actavis and Valeant

US FDA approves NDA from Actavis and Valeant

26-03-2014

US generics major Actavis and Canada’s Valeant Pharmaceuticals said that the US Food and Drug Administration…

ActavisCanadaGenericsMetronidazolePharmaceuticalRegulationUSAValeant PharmaceuticalsWomen's Health

Actavis challenges Multaq and Colcrys patents

02-03-2014

Ireland-headquartered generic drugmaker Actavis revealed on Friday (February 28) that French pharma giant…

ActavisAnti-Arthritics/RheumaticsCardio-vascularColcrysGenericsLegalMultaqNorth AmericaPatents & Trade marksRegulationSanofiTakeda PharmaceuticalsUSA

Actavis confirms challenge to Allergan’s Restasis

22-01-2014

Generics drug major Actavis has confirmed that its Watson Laboratories unit has submitted an Abbreviated…

ActavisAllerganGenericsNorth AmericaOphthalmicsPatentsRegulationRestasisUSAWatson Pharmaceuticals

FTC approves final order regarding Actavis’ acquisition of Warner Chilcott

FTC approves final order regarding Actavis’ acquisition of Warner Chilcott

12-12-2013

Following a public comment period, the US Federal Trade Commission has approved a final order settling…

ActavisGenericsMergers & AcquisitionsNorth AmericaRegulationReproductiveWarner Chilcott

Actavis confirms challenge of Lilly’s Axiron patent

Actavis confirms challenge of Lilly’s Axiron patent

14-11-2013

US generics major Actavis confirms that it has filed an Abbreviated New Drug Application with the US…

ActavisAxironEli LillyGenericsLegalMen's HealthNorth AmericaPatentsRegulation

Actavis confirms Vimpat patent challenge and gets OK for generic Opana

15-07-2013

US generics major Actavis (NYSE: ACT) confirmed on Friday (July 12) that it has filed an Abbreviated…

ActavisEndo Health SolutionsGenericsLegalNeurologicalNorth AmericaOpana ERPatentsRegulationUCBVimpat

Actavis confirms patent challenge on Bayer's Safyral

06-06-2013

USA-based generics major Actavis (NYSE: ACT) yesterday (June 5) confirmed that it has filed an Abbreviated…

ActavisBayerGenericsPatentsRegulationReproductiveSafyralWomen's Health

Actavis confirms patent challenge to Endo's Fortesta

04-03-2013

Generics drug giant Actavis (NYSE: ACT, formerly trading as Watson) has confirmed filing an Abbreviated…

ActavisEndo PharmaceuticalsFortestaGenericsMen's HealthNorth AmericaPatentsRegulation

Actavis settles with Mallinckrodt over Exalgo 32mg; Teva gains FDA OK for Adderall XR

14-02-2013

US generics drug major Actavis (NYSE: ACT) has reached a settlement with Mallinckrodt (NYSE: MKG) on…

ActavisAdderall XRExalgoGenericsMallinckrodtNeurologicalNorth AmericaPatentsRegulationShireTeva Pharmaceutical Industries

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

US FDA approves generics for Actavis and Lupin

06-07-2012

Switzerland-based generic drugmaker Actavis Group, now owned by US firm Watson Pharmaceuticals (NYSE:…

ActavisGenericsIntunivLupinLyricaNeurologicalNorth AmericaPfizerRegulationShireWatson Pharmaceuticals

Shire to face generic competition for Adderall XR from Actavis

25-06-2012

Shares in UK drugmaker Shire (LSE: SHP) fell around 9% to £17.82 in early trading this morning,…

ActavisAdderall XRGenericsNeurologicalNorth AmericaPharmaceuticalRegulationShireWatson Pharmaceuticals

1 to 25 of 26 results

Back to top